Leeanne Ardoin
Family · Ville Platte, LANPI 1003346768
Payments from drug & device makers
Across 374 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$962
- Sumitomo Pharma America, Inc.$473
- Novo Nordisk$445
- Takeda Pharmaceuticals U.S.A., Inc.$384
- GSK$322
- AstraZeneca$302
- plus $3K from 36 others
What the payments were for
- Food & beverage$5,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,703 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $36,077 |
| MounjaroTirzepatide | 31 | $35,131 |
| FarxigaDapagliflozin Propanediol | 25 | $18,214 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,679 |
| JardianceEmpagliflozin | 25 | $12,621 |
| JanuviaSitagliptin Phosphate | 15 | $7,360 |
| EliquisApixaban | 11 | $7,117 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $6,434 |
| Lurasidone Hcl | 14 | $1,938 |
| Icosapent Ethyl | 13 | $1,585 |
| Diclofenac Sodium | 55 | $876 |
| Rosuvastatin Calcium | 129 | $777 |
| Omeprazole | 50 | $690 |
| Gabapentin | 47 | $674 |
| Amlodipine Besylate | 135 | $652 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $445 | $36,07738 claims |
| Lilly USA, LLCMounjaro | $293 | $35,13131 claims |
| Boehringer IngelheimJardiance, Synjardy | $272 | $19,05536 claims |
| AstraZenecaFarxiga | $302 | $18,21425 claims |
| GSKTrelegy Ellipta | $322 | $14,67913 claims |
| MerckJanuvia | $102 | $7,36015 claims |
| PfizerEliquis | $217 | $7,11711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Ville Platte
- Brittany MillerVille Platte$158K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.